PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
PostNews: Interim Report
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
PostNews: Press Release
PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share
PHI has appointed Pareto Securities as the Company’s liquidity provider.
PostNews: Press Release
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
PostNews: Press Release
Directed issue registered at the Companies Registration Office
PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
Life is a mess
In our daily lives, we all know how important it is to plan ahead to avoid a future mess. Ironically, we ourselves are such a future mess.
Fighting cancer with nanoparticles
Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.
No Blood, No Tumor
Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.
Big Data, Fewer Cells
Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
